Accessibility Menu
enVVeno Medical logo

enVVeno Medical(NASDAQ) HJLI

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-95%
1 Year-94%
1 Month-9%
N/A
enVVeno Medical last closing stock price
MetricPriceDate
Last closeUSD 10.392026-07-24
enVVeno Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.75%USD 10.802026-07-17
1 month-8.62%USD 11.372026-06-24
3 month-20.08%USD 13.002026-04-24
Year to date-7.46%USD 11.232025-12-31
1 year-94.09%USD 175.702025-07-24
3 year-94.36%USD 184.102023-07-25
5 year-95.19%USD 215.952021-07-23
Since inception-99.77%USD 4,585.002018-05-31

enVVeno Medical Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$18.82M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 11, 2021

HJLI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About enVVeno Medical

enVVeno develops medical devices for people with severe leg vein problems. Its main products aim to help those with chronic venous insufficiency, a condition where leg veins cannot send blood back to the heart properly. These devices are designed to improve mobility and reduce pain for affected patients.

Gadgets for Good Circulation: Products and Services

  • VenoValve: Surgical implant for severe chronic venous insufficiency; no revenue contribution as of 2025.
  • enVVe System: Minimally invasive, non-surgical valve replacement in pre-clinical development; no revenue contribution as of 2025.
  • Proprietary Manufacturing: In-house production of bioprosthetic valves using specialized tissue processing; supports all product development.
  • Research and Development: Focused on new treatments for deep vein disease; no revenue contribution as of 2025.

From Valves to Value: Growth and Expansion

  • Shifted focus from the VenoValve to the enVVe System after 2025 FDA decision.
  • Completed pre-clinical testing for enVVe System in 2025; FDA trial discussions began late 2025.
  • Expanded manufacturing in Irvine, California, with capacity for up to approximately 20,000 valves per year since 2025.
  • Raised capital through public offerings in 2024 and late 2025 to fund development.

Why enVVeno Stands Out (Without Standing on Ceremony)

enVVeno holds 42 patents and uses proprietary tissue processing to reduce immune reactions. Its facility is certified for medical device manufacturing and can scale production quickly. The company’s leadership brings experience in device development and regulatory navigation.

Five Things You Need to Know

  • No revenue reported for 2023–2025; company remains pre-commercial.
  • Net loss was $19.5 million in 2025, down 11% from 2024.
  • Research and development expenses fell 19% to $10.0 million in 2025.
  • Cash and investments totaled $28.2 million at December 31, 2025.

Bottom Line

enVVeno has shifted from surgical to minimally invasive solutions for vein disease. The company’s future depends on successful clinical trials and regulatory approval.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

33

CEO

Robert Andrew Berman

Website

www.envveno.com

Headquarters

Irvine, CA 92618, US

HJLI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-66.39%

Return on Capital

-75.10%

Return on Assets

-72.11%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$20.01M

EBITDA

$4.99M

Operating Cash Flow

-$14.79M

Capital Expenditure

-$5.00K

Free Cash Flow

-$14.79M

Cash & ST Invst.

$24.93M

Total Debt

$603.00K

enVVeno Medical Performance Analysis

enVVeno Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
enVVeno Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
enVVeno Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -76.8815.4%
20232023-12-31USD -66.91-13.0%
20242024-12-31USD -44.55-33.4%
20252025-12-31USD -33.06-25.8%
enVVeno Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-50.0%
Q32025-09-3030.3%
Q42025-12-31-13934.8%
Q12026-03-3181.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

19

N/A

Net Income

-$3.85M

+14.5%

EBITDA

$124.00K

+102.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$24.93M

-36.0%

Total Debt

$603.00K

-38.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$207.00K

-66.0%

Short Term Debt

$396.00K

+7.0%

Return on Assets

-72.11%

N/A

Return on Invested Capital

-83.52%

N/A

Free Cash Flow

-$3.24M

+19.4%

Operating Cash Flow

-$3.24M

+19.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ICADiCAD, Inc.
$3.87+3.75%
NVCNNeovasc Inc.
$30.03+0.00%
FVEFive Star Senior Living Inc.
$2.94+2.44%
NAKANakamoto Inc.
$4.69-3.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About HJLI

What is the current price of enVVeno Medical?

enVVeno Medical is trading at N/A per share.

What is the 52-week range for enVVeno Medical?

Over the past 52 weeks, enVVeno Medical has traded between N/A and N/A.

How much debt does enVVeno Medical have?

As of the most recent reporting period, enVVeno Medical reported total debt of $603.00K.

How much cash does enVVeno Medical have on hand?

enVVeno Medical reported $2.60M in cash and cash equivalents in its most recent financial results.

What is enVVeno Medical’s dividend yield?

enVVeno Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services